PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D reduction while AGEN shows 20.36% growth. Joel Greenblatt would examine competitive risk.
108.24%
G&A growth above 1.5x AGEN's 6.94%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-3.86%
Operating expenses reduction while AGEN shows 6.94% growth. Joel Greenblatt would examine advantage.
-3.86%
Total costs reduction while AGEN shows 16.70% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while AGEN shows 3.64% growth. Joel Greenblatt would examine advantage.
-1.12%
D&A reduction while AGEN shows 13.23% growth. Joel Greenblatt would examine efficiency.
-1.49%
EBITDA decline while AGEN shows 42.48% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth below 50% of AGEN's 45.68%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.47%
Pre-tax income decline while AGEN shows 35.93% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-1.47%
Net income decline while AGEN shows 35.93% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS growth below 50% of AGEN's 36.04%. Michael Burry would check for structural issues.
13.49%
Diluted EPS growth below 50% of AGEN's 36.04%. Michael Burry would check for structural issues.
16.41%
Share count reduction below 50% of AGEN's 0.24%. Michael Burry would check for concerns.
17.29%
Diluted share reduction below 50% of AGEN's 0.24%. Michael Burry would check for concerns.